Evolva to enter the Swiss SPI stock index

Reinach, Switzerland, 22 March 2011 - Evolva Holding SA (SIX: EVE; ISIN 0021218067) today announced that the Evolva share will be included in the broad Swiss Performance Index (SPI ® ) starting 4 April 2011.

Based on the rules governing the SPI Index family, only equities with a free float exceeding 20% can be included. Since the partial release of the locked up shares in December 2010, Evolva’s free float complies with this condition. As a consequence, the Index Commission has recommended including Evolva in the SPI index.

Neil Goldsmith, CEO & Managing Director of Evolva, said “Some institutional investors are barred from investing in stocks outside the SPI. Our inclusion in the SPI index reflects our increased free float and broadens our potential investor base. We see this as another positive step in our transition from a private into a broadly owned public company.”

About Evolva Holding SA
Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in Pharma and in the area of Consumer Health, Nutrition and Food Chain. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications.

For more information see www.evolva.com.

Contact Details

Neil Goldsmith, CEO                     Jakob Dynnes Hansen,CFO                         Paul Verbraeken, IR
neilg@evolva.com                          jakobdh@evolva.com                                     paulv@evolva.com
+ 41 61 485 2005                           + 41 61 485 2034                                            + 41 61 485 2035

Capital MSL

Mary Clark, Justine Lamond and Hollie Vile             evolva@capitalmsl.com            +44 (0)20 7307 5337

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forwardlooking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.